Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized muscle training may ease leg pain from blocked arteries

NCT ID NCT04800276

Symptom relief Sponsor: Centre Hospitalier le Mans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether a personalized exercise program—focusing on the specific leg muscles affected by blocked arteries—can help people with peripheral arterial disease walk longer distances without pain. Participants are randomly assigned to either a tailored muscle-strengthening program or a general strengthening program. The goal is to see if targeting the exact areas of poor blood flow leads to greater improvements in walking ability and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
adapted physical activity (muscle strengthening)
What this could lead to
If it works, this approach could offer a more effective exercise program to help people with peripheral arterial disease walk farther and feel better.
What could go wrong
This is a small, early-stage study with 70 participants, so results may not apply to everyone. Exercise programs require ongoing commitment, and benefits may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2021

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with Lower Limb Peripheral Arterial Disease with IPSC \< 0.90, arterial stenosis in the lower limbs and intermittent claudication * No contraindication to physical activity * Socially insured patients over 18 ; * Patient who has signed the consent form. Exclusion Criteria: * Severe or unstable cardiopulmonary pathologies, contraindicating exercise training * Unstable angina or myocardial infarction \<3 months * Severe rheumatological pathology of the lower limbs * Amputee of a lower or upper limb fitted with a device * Extensive dermatosis of the lower limbs * Known NYHA grade III or IV heart failure * Known severe respiratory pathology * Parkinson's disease, hemiplegia or paraplegia * Adults subject to enhanced protection, deprived of their liberty by judicial or administrative decision * Persons unable to consent * Be in a period of exclusion from other interventional research. * Any event (injury, surgery, etc.) occurring during the protocol period that could have an impact on results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral arterial disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peripheral arterial disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Du Mans

    RECRUITING

    Le Mans, 72000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.